These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 20381925)
21. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. Burgess DS; Hall RG Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs. Papich MG Vet Microbiol; 2014 Jul; 171(3-4):480-6. PubMed ID: 24513278 [TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Li C; Du X; Kuti JL; Nicolau DP Antimicrob Agents Chemother; 2007 May; 51(5):1725-30. PubMed ID: 17307978 [TBL] [Abstract][Full Text] [Related]
25. Selecting antibiotics based on pharmacokinetic and pharmacodynamic principles. Klutman NE Pharm Pract Manag Q; 1996 Jul; 16(2):9-12. PubMed ID: 10161616 [TBL] [Abstract][Full Text] [Related]
26. New pharmacodynamic parameters for antimicrobial agents. Li RC Int J Antimicrob Agents; 2000 Feb; 13(4):229-35. PubMed ID: 10755236 [TBL] [Abstract][Full Text] [Related]
27. [Pharmacokinetic and pharmacodynamic concepts for an interpretative reading of the antibiogram]. Soriano F Enferm Infecc Microbiol Clin; 2002 Oct; 20(8):407-11; quiz 412. PubMed ID: 12372239 [TBL] [Abstract][Full Text] [Related]
29. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Li RC; Zhu M; Schentag JJ Clin Pharmacokinet; 1999 Jul; 37(1):1-16. PubMed ID: 10451780 [TBL] [Abstract][Full Text] [Related]
30. EUCAST expert rules in antimicrobial susceptibility testing. Leclercq R; Cantón R; Brown DF; Giske CG; Heisig P; MacGowan AP; Mouton JW; Nordmann P; Rodloff AC; Rossolini GM; Soussy CJ; Steinbakk M; Winstanley TG; Kahlmeter G Clin Microbiol Infect; 2013 Feb; 19(2):141-60. PubMed ID: 22117544 [TBL] [Abstract][Full Text] [Related]
31. The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens. Maglio D; Nicolau DP Methods Find Exp Clin Pharmacol; 2004 Dec; 26(10):781-8. PubMed ID: 15672121 [TBL] [Abstract][Full Text] [Related]
32. Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond. Rao GG; Landersdorfer CB Int J Antimicrob Agents; 2021 Aug; 58(2):106368. PubMed ID: 34058336 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Theuretzbacher U Clin Infect Dis; 2012 Jun; 54(12):1785-92. PubMed ID: 22437238 [TBL] [Abstract][Full Text] [Related]
34. Limitations of MIC as the sole criterion in antimicrobial drug dosage regimen design: the need for full characterization of antimicrobial pharmacodynamic profile especially for drug-resistant organisms. Gehring R; Riviere JE Vet J; 2013 Oct; 198(1):15-8. PubMed ID: 24025153 [No Abstract] [Full Text] [Related]
35. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Dudley MN; Ambrose PG Curr Opin Microbiol; 2000 Oct; 3(5):515-21. PubMed ID: 11050452 [TBL] [Abstract][Full Text] [Related]